A case report describes a patient who experienced lucid dreams after taking pregabalin, a medication used for neuropathic pain and anxiety. The report suggests that pregabalin may induce lucid dreaming, which could have implications for clinical practice, particularly regarding patient counseling and monitoring. The authors propose that this effect might be related to pregabalin's modulation of calcium channels and its impact on sleep architecture. The finding indicates that clinicians should be aware of this potential side effect when prescribing pregabalin.
This review examines mindfulness-oriented recovery enhancement (MORE) as an intervention for chronic pain and opioid addiction, proposing that it disrupts the downward spiral linking these conditions. The authors review clinical outcomes and neurocognitive targets, suggesting that MORE may reduce pain and opioid misuse by targeting mechanisms such as reward processing, cognitive control, and stress reactivity. They argue that MORE offers a promising adjunct to standard treatments, though they note the need for further research to establish its efficacy across diverse populations.